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lowing three criteria: 1) diagnosis of diabetes mellitus; 2) pre-
scription of oral anti-diabetic drug; and 3) fasting blood or
plasma glucose value indicative of diabetes. The average length
of follow-up upon inclusion was 4.5 years. METHODS: Costs
of inpatient care were estimated by classifying hospitalisations
of study patients into diagnosis-related groups (DRGs) accord-
ing to the Nord-DRG classiﬁcation system and assigning average
costs per DRG (2002 prices) according to a national list relying
on individual patient level costs incurred at Swedish hospitals
applying the Nord-DRG system. Costs of outpatient care were
estimated by assigning unit costs of outpatient care-giver con-
tacts obtained from published sources to data on study patients’
care-giver contacts as recorded in medical records at participat-
ing primary care centres. RESULTS: The average annual cost of
inpatient care over the studied years was €1088 per patient (SD
€4460; n = 9292 on average). Between 2000 and 2004, an annual
increase in costs of between 9% and 15% was observed (con-
stant prices). The average annual cost of outpatient care during
the studied years was €363 per patient (SD €437) with little vari-
ation over the years. GP visits accounted for 40% of outpatient
costs, the average patient making 1.7 GP visits per year. CON-
CLUSIONS: Diabetes continues to impose a heavy economic
burden on society. Cost estimates from this population-based
sample of Swedish diabetic patients may serve as reference values
for a Swedish setting.
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OBJECTIVES: The RESULT study demonstrated that sulphony-
lurea (SU) plus rosiglitazone (RSG) provided a sustained and
substantial increase in beta-cell function (BCF) from baseline
(56%, p < 0.0001) compared to SU alone (6%, p = 0.41). This
modelling study explores the impact on disease progression,
health outcomes and health care expenditure in Portugal of 
different approaches to modelling RSG’s effect on BCF.
METHODS: DiDACT, a peer-reviewed published long-term
model of T2DM, was used to replicate patient characteristics
(73% Male, mean age 68.2 years, mean BMI 30 kg/m2) and the
impact of SU + RSG on BCF observed in the RESULT study using
an additive, a multiplicative or combined approach. Disease pro-
gression for 1000 hypothetical patients, projected total lifetime
health care costs and health gains, measured in time to insulin
and quality-adjusted life years (QALYs) were predicted. Follow-
ing failure of intermediate SU dose to maintain glycaemic target,
up-titrated SU therapy was compared to SU + RSG combination.
The treatment change threshold was HbA1C ≥ 7.5%. Resources
were valued using national unit costs from a variety of sources.
Costs and outcomes were discounted at 5% per year. RESULTS:
Both revised calibrations yielded lower lifetime health care costs
and additional QALYs, compared to the original calibration.
Compared with SU alone both revised calibrations resulted in
lower incremental cost-effectiveness ratios (ICERs). Each repre-
sentation of RSG showed greater time to insulin than SU alone
(13 years); the additive approach substantially extended viabil-
ity of oral therapy to 27.5 years compared to 20 years for mul-
tiplicative and original calibrations. CONCLUSIONS: Each
modelling approach resulted in reduced costs, increased QALYs
and time to insulin when compared with the original calibration.
The use of RSG in the management of T2DM appears to be cost-
effective in all scenarios investigated. Forthcoming long-term
studies of RSG may conﬁrm the impact of RSG on BCF observed
and enable determination of the most appropriate method for
model calibration.
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OBJECTIVES: The co-epidemics of obesity and type II diabetes
and associated complications result in an increasing population
with high risk of serious morbidity, mortality and reduced
quality of life. This analysis has been speciﬁcally developed to
estimate the cost per quality adjusted life year (QALY) gained
with orlistat compared to standard clinical practice (SCP) in a
particularly high-risk diabetic population with morbid obesity
(BMI > 35 kg/m2 and at least one additional CVD risk). In
Norway this is a population with clearly unmet needs for pre-
ventive medical interventions. METHODS: The incremental
cost-utility is calculated in an Excel-model comparing 1 year of
orlistat treatment followed by 9 years of SCP with 10 years of
SCP. The baseline risk is based on the ﬁndings of the UK Pre-
ventive Diabetes Study (UKPDS), adjusted for differences in
BMI. The effects of orlistat and SCP (conservatively assumed
equal to placebo + SCP) on risk factors (BMI, HbA1c, LDL-cho-
lesterol, SBP), are based on results from the relevant randomized
clinical trials. 3 years catch-up of risks after termination of orli-
stat is assumed. UKPDS and the Heart Protection Study provide
assessments of the change in risk associated with change in
HbA1c and the other relevant risk factors. Effects on utility are
based on the results from CODE-2. Direct costs related to the
treatment alternatives and their associated complications are
included from a Norwegian societal perspective. RESULTS: The
expected incremental cost of treating high-risk Norwegian dia-
betic morbid obese patients with orlistat is approximately
€3125/QALY. Extensive one- and multiway sensitivity analyses
using Monte Carlo simulation indicate robustness of the results.
CONCLUSIONS: The results of this model indicate that one
year treatment with orlistat is a highly cost-effective alternative
to SCP for diabetic patients with morbid obesity and additional
CVD risk in Norway.
PDB28
INADEQUATE GLYCEMIC CONTROL: IS IT RELATED WITH
MORE COMORBIDITIES AND MORE RESOURCE UTILIZATION?
Sicras A1, Navarro R1, González P2, Sánchez C2, F Bobadilla J2,
Soto J2
1Badalona Servicios Asistenciales, Barcelona, Spain, 2Pﬁzer Spain,
Madrid, Spain
OBJECTIVE: To evaluate the inﬂuence of inadequate glycemic
control (IC) in comorbidity and health resource utilization of
type 2 diabetic patients treated in a general practitioner setting.
METHODS: Retrospective observational study (systematic-sam-
pling) of patients older than 18 years, treated in 5 primary care
centres during 2005. The following parameters were evaluated:
IC, deﬁned by HbA1c > 7%; age; sex; comorbidities (hyperten-
sion, hypercholesterolemia, smoking, obesity, ischemic-heart-
disease, cardiovascular event (CVE), COPD, depression,
cardiac-renal-hepatic insufﬁciency, microvascular complica-
tions); clinical parameters (BMI, total-cholesterol, LDL-Friede-
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wald, HDLc, glucose, triglycerides); and resources utilization
(specialist referrals, medical visits, drugs, tests). A logistic regres-
sion analysis was used to correct the model (IC as the dependent
variable). Costs were contrasted by a multivariate ANCOVA
analysis with marginal means estimation (Bonferroni-adjust),
using SPSS 12.0 and a statistical signiﬁcance of p < 0.05.
RESULTS: 5014 patients were evaluated; mean age was 64.6 ±
12.1; 50.3% were men; 16.1% had a history of a CVE and
27.4% had IC (CI95%:26.2–28.6%). Suffering a CVE (OR =
1.2; CI95%:1.0–1.4; p = 0.021), smoking (OR = 1.2;
CI95%:1.0–1.4; p = 0.017) and retinopathy (OR = 1.5;
CI95%:1.3–1.7; p = 0.000) were independently related with IC.
Clinical parameters and resources utilization were different in IC
vs. good control patients: glucose 181.7 ± 61.8 vs. 129.1 ± 32.0
mg/dl (p = 0.000); LDLc 122.4 ± 38.0 vs. 119.7 ± 35.48 mg/dl
(p = 0.018); mean number of oral antidiabetics was 1.3 ± 0.8 vs.
1.2 ± 0.6 (p = 0.002); and insulins 0.5 ± 0.6 vs. 0.1 ± 0.4 (p =
0.000). Total cost/patient/year adjusted with covariance was
1.953.86€ (EE = 73.7) in patients with inadequate control versus
1.747.48€ (EE = 36.2) with good control (p = 0.03). The phar-
maceutical cost represents a 74.2% overall resources utilization
costs in both good and inadequate controlled patients. CON-
CLUSIONS: Smoking, CVE and retinopathy were independently
related with inadequate glycemic control. Uncontrolled diabetic
patients have a worse lipid proﬁle and a higher glucose level
despite a higher use of oral antidiabetics and insulin, and repre-
sent a higher cost/patient/year. General practice centres should
promote speciﬁc interventions to improve glycemic control in
diabetic patients.
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OBJECTIVES: Based on the type 2 diabetes cohort of the
DETECT study (Curr Med Res and Opinion; 2005; 21/4:
619–29) simulations with the EAGLE Diabetes Model (Diab
Technology & Therapeutics; 2006; 8/2: 219–36) were con-
ducted. Development of long-term complications was compared
with respect to different treatment targets for HbA1c. Addition-
ally, the outcome for a mixed patient population typically for a
general practice was assessed. METHODS: The Economic
Assessment of Glycemic Control and Longterm Effects (EAGLE)
model simulates long-term effects of diabetes treatment and
related costs. Baseline characteristics of the simulation cohorts
corresponded to type 2 patients of the DETECT study with
HbA1c > 9%: age 63 ± 11 years, diabetes duration 9 ± 7 years,
49% male, hypertension prevalence 71%, mean HbA1c 10,1 ±
1,3%. Three cohorts with different HbA1c targets were deﬁned:
a) no change; b) 8%; and c) 6.4%. A fourth cohort was com-
posed of 25% patients with target a) 60% target; b) and 15%;
and target c). All cohorts achieve respective targets within one
year followed by a yearly increase of 0.2%. Simulations were
run with 1000 patients over 10 years. RESULTS: The relative
risk reduction comparing cohort b versus no change was 19%
(MI); 17% (stroke); 12% (PAD); 7% (prolif. retinopathy); and
4% (ESRD). A treatment target according to the German dia-
betes guideline (c versus a) resulted in reductions of 30%, 27%,
20%, 11%, and 6%, respectively. Analysing the mixed cohort
demonstrated that treatment effects were similar to the results of
cohort b. CONCLUSIONS: The simulations based on a German
diabetes population demonstrate the long-term effects of various
treatment targets for HbA1c. Although a steady re-increase of
HbA1c values was assumed a signiﬁcant reduction in micro- and
macrovascular events can be achieved. Simulations of a mixed
cohort correlate to real world patient groups and could be used
for cost estimations in practice settings.
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OBJECTIVE: to assess the economic and epidemiologic impact
of diabetes in Campania a region of approximately 5.7 million
inhabitants in the south of Italy. METHOD: we collected, from
an electronic database, all prescriptions for antidiabetic drugs
reimbursed in the ﬁrst half year of 2005 in 8 local health author-
ities (60% of the overall population) of Campania. The diabetic
cohort was deﬁned as the population of subjects receiving at least
one prescription of an antidiabetic agent, classiﬁed according to
their therapeutic role using Anatomic Therapeutic Chemical
(ATC) classiﬁcation. We identiﬁed 3 groups: who received only
insulin (A) or only oral blood glucose lowering drugs (B) or both
(C). Drugs cost and drugs consumption were quantiﬁed using
NHS prospective (expressed in Euro 2005) and Deﬁned Daily
Dose system (DDD) respectively. RESULTS: The diabetic cohort
included 200,070 subjects (5.7% of the observed population):
15.3% group A (mean age 62.7 ± 17.9 y.o., 0.78 M/F), 78.5%
group B (mean age 65.7 ± 12.2 y.o., 0.85 M/F) and 6.2% group
C (mean age 66.5 ± 11.1 y.o., 0.57 M/F). The mean
drug/cost/patient was: 524.6€ group A (36.6% insulin, 27.1%
cardiovascular drugs), €290.4 group B (11.1% oral hypo-
glycemic drugs, 47.1% cardiovascular drugs) and €649.8 group
C (25.7% insulin, 5.4% oral hypoglycemic drugs, 34.6% car-
diovascular drugs). Total cost for diabetic patients represents
17.8% of the total expenditures. CONCLUSION: Chronic-
degenerative pathologies, such as diabetes, implies a relevant
social and economic impact. Expenses that are associated to the
treatment and the prevention of complications, in particular car-
diovascular problems, are registered among the main items listed
in the health care budget. Among diabetics patients the high use
of drugs for cardiovascular problems is the cost driver.
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OBJECTIVE: This study is to investigate the impact of the
National Health Insurance (NHI) reimbursement price on the
utilization of brand name oral hypoglycemic agents (OHAs) and
its generic counterparts for ambulatory care under an institu-
tional context characterized by a health care system being lack
of separating drug prescribing and dispensing as well as a hos-
pital system with a large outpatient department, likely resulting
in the monopsony power of hospitals over the wholesale market
of pharmaceuticals. METHODS: Data is from the National
Health Insurance Database 1997–2004 with 29,253 diabetic
patient cohort data in 7 years. Patients’ severity is measured by
the types of combination pharmacological therapy. The two-part
model was used to estimate the effect of reimbursement price on
